Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Key Inclusion Criteria:

• Previously treated individuals with inoperable metastatic colorectal cancer (mCRC)who are ineligible for checkpoint inhibitor therapy (microsatellite instability (MSI)-H or mismatch repair deficient (dMMR) and are excluded).

• Histologically or cytologically confirmed adenocarcinoma originating in the colon orrectum (excluding appendiceal and anal canal cancers) who have progressed on orafter 1 prior systemic therapy in the setting where curative resection is notindicated. This therapy must have included chemotherapy based on 5-fluorouracil (5-FU) or capecitabine with oxaliplatin and either bevacizumab, or for individualswith rat sarcoma (RAS) wild-type and left-sided tumors, bevacizumab, cetuximab, orpanitumumab.

• Measurable disease (Response Evaluation Criteria in Solid Tumors (RECIST) V1.1criteria).

• Individuals must have an eastern cooperative oncology group (ECOG) performancestatus of 0 or 1.

• Life expectancy of at least 12 weeks.

• Laboratory measurements, blood counts: adequate hemoglobin, neutrophil, and plateletcounts

• Adequate liver function.

• Adequate renal function.

Key Exclusion Criteria:

• Prior anticancer therapy including chemotherapy, hormonal therapy, orinvestigational agents within 3 weeks or within at least 4 half-lives prior tomagrolimab dosing (up to a maximum of 4 weeks), whichever is shorter.

• Known v-raf murine sarcoma viral oncogene homolog B1 gene mutation (BRAF V600E) orMSI-H mutations or dMMR.

• Persistent Grade 2 or more gastrointestinal bleeding.

• Individuals with prior irinotecan therapy.

• Clinically significant coronary artery disease or myocardial infarction within 6months prior to inclusion.

• Peripheral neuropathy of more than Grade 2 (Common Terminology Criteria for AdverseEvents (CTCAE) Version 5.0).

• Known dihydropyrimidine dehydrogenase deficiency.

• Acute intestinal obstruction or sub-obstruction, history of inflammatory intestinaldisease or extended resection of the small intestine. Presence of a colonicprosthesis.

• Unhealed wound, active gastric or duodenal ulcer, or bone fracture.

• History of abdominal fistulas, trachea-oesophageal fistulas, any other Grade 4gastrointestinal perforations, nongastrointestinal fistulas, or intra-abdominalabscesses 6 months prior to screening.

• Uncontrolled arterial hypertension.

• Thromboembolic event in the 6 months before inclusion (eg, transitory ischemicstroke, stroke, subarachnoid hemorrhage) except peripheral deep vein thrombosistreated with anticoagulants.

• Active central nervous system (CNS) disease. Individuals with asymptomatic andstable, treated CNS lesions (radiation and/or surgery and/or other CNS-directedtherapy who have not received corticosteroids for at least 4 weeks) are allowed.

• Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 unitsof packed RBC transfusions during the 4-week period prior to screening.

• History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in thelast 3 months.

• Known hypersensitivity to any of the study drugs, the metabolites, or formulationexcipient.

• Known inherited or acquired bleeding disorders.

• Significant disease or medical conditions, as assessed by the investigator andsponsor, that would substantially increase the risk-benefit ratio of participatingin the study.

• Second malignancy, except treated basal cell or localized squamous skin carcinomas,or localized prostate cancer.

• Uncontrolled pleural effusion.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.